These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 21215810

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
    Jaskula E, Lange A, Kyrcz-Krzemien S, Markiewicz M, Dzierzak-Mietla M, Jedrzejczak WW, Czajka P, Mordak-Domagala M, Lange J, Gronkowska A, Nowak J, Warzocha K, Hellmann A, Kowalczyk J, Drabko K, Gozdzik J, Mizia S, Polish Donor-Recipient Matching Group.
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation.
    Holler E, Rogler G, Brenmoehl J, Hahn J, Greinix H, Dickinson AM, Socie G, Wolff D, Finke J, Fischer G, Jackson G, Rocha V, Hilgendorf I, Eissner G, Marienhagen J, Andreesen R.
    Int J Immunogenet; 2008 Aug; 35(4-5):381-4. PubMed ID: 18976442
    [Abstract] [Full Text] [Related]

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 8. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children.
    Gruhn B, Intek J, Pfaffendorf N, Zell R, Corbacioglu S, Zintl F, Beck JF, Debatin KM, Steinbach D.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1571-7. PubMed ID: 19896081
    [Abstract] [Full Text] [Related]

  • 9. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
    Wermke M, Maiwald S, Schmelz R, Thiede C, Schetelig J, Ehninger G, Bornhäuser M, Wassmuth R.
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
    [Abstract] [Full Text] [Related]

  • 10. NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation.
    van der Velden WJ, Blijlevens NM, Maas FM, Schaap NP, Jansen JH, van der Reijden BA, Feuth T, Dolstra H, Donnelly JP.
    Bone Marrow Transplant; 2009 Aug; 44(4):243-8. PubMed ID: 19219079
    [Abstract] [Full Text] [Related]

  • 11. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.
    Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R, Ottinger H, Rath PM, Ross RS, Roggendorf M, Grosse-Wilde H, Beelen DW.
    Transplantation; 2006 Jan 27; 81(2):247-54. PubMed ID: 16436969
    [Abstract] [Full Text] [Related]

  • 12. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation.
    Madrigal A, Shaw BE.
    Blood Cells Mol Dis; 2008 Jan 27; 40(1):40-3. PubMed ID: 17964196
    [Abstract] [Full Text] [Related]

  • 13. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME, Kornblit B, Larsen MV, Masmas TN, Nielsen M, Thiim M, Garred P, Stryhn A, Lund O, Buus S, Vindelov L.
    Biol Blood Marrow Transplant; 2010 Oct 27; 16(10):1370-81. PubMed ID: 20353833
    [Abstract] [Full Text] [Related]

  • 14. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A, Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Am J Hematol; 2007 Oct 27; 82(10):863-6. PubMed ID: 17616972
    [Abstract] [Full Text] [Related]

  • 15. No impact of NOD2/CARD15 on outcome after SCT.
    Sairafi D, Uzunel M, Remberger M, Ringdén O, Mattsson J.
    Bone Marrow Transplant; 2008 Jun 27; 41(11):961-4. PubMed ID: 18317454
    [Abstract] [Full Text] [Related]

  • 16. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y.
    Biol Blood Marrow Transplant; 2010 Jun 27; 16(6):838-47. PubMed ID: 20109568
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb 27; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 18. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 27; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 27; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 20. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation.
    Krüger B, Böger CA, Schröppel B, Obed A, Hoffmann U, Murphy BT, Fischereder M, Holler E, Banas B, Krämer BK.
    Transpl Int; 2007 Jul 27; 20(7):600-7. PubMed ID: 17498224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.